FDA approves Moderna's next-generation COVID-19 vaccine

In an official statement, Moderna said the FDA has approved the mNEXSPIKE vaccine for people aged 12-64 with at least one underlying health risk factor.

On May 31, the US Food and Drug Administration (FDA) approved Moderna's new generation COVID-19 vaccine mNEXSPIKE for adults aged 65 and over.

This is the first vaccine approved by the FDA since the agency tightened its licensing standards.

In an official statement, Moderna said the FDA has also approved the mNEXSPIKE vaccine for people aged 12-64 with at least one underlying health risk factor.

The move comes as the US Department of Health and Human Services (HHS) is stepping up its oversight of the vaccine approval process.

Earlier on May 20, the FDA announced that it would require drugmakers to test their COVID-19 vaccine boosters in healthy adults under 65 years old if they want approval.

This means that the use of the new vaccine will be indicated for the elderly and those at high risk.

mNEXSPIKE, which can be stored in a refrigerator instead of a freezer, extends shelf life and simplifies distribution, especially in developing countries facing supply chain challenges during mass vaccination campaigns.

To date, the US Centers for Disease Control and Prevention (CDC) still recommends that both healthy children and parents should get vaccinated against COVID-19 to protect their health./.

(Vietnam+)

Source: https://www.vietnamplus.vn/fda-phe-duyet-vaccine-phong-covid-19-the-he-moi-cua-moderna-post1041748.vnp